ヤヌスキナーゼ（JAK）阻害剤の世界市場 2024-2032年

世界のヤヌスキナーゼ（JAK）阻害剤市場は2023年に132億3,000万米ドルに達し、2032年には297億6,000万米ドルに達すると予測され、予測期間2024年にはCAGR 8.4%で成長する見込みです。

パイプライン医薬品

ヤヌスキナーゼは、サイトカインシグナル伝達経路に関与するタンパク質群です。これらは、いくつかの自己免疫疾患、アレルギー性疾患、炎症性疾患において重要な役割を果たすことが知られています。特にJAK1、JAK2、JAK3、TYK2と名付けられた4つのヤヌスキナーゼ（JAK）タンパク質があります。これらは7つの転写因子（STAT）と相互作用し、サイトカイン受容体の下流で細胞内シグナル伝達を媒介します。

ヤヌスキナーゼ（JAK）阻害剤は様々な病態に適応のある薬剤で、特にヤヌスキナーゼ経路を阻害することが知られています。JAK1は、そう痒性皮膚炎、アレルギー性鼻炎、喘息、炎症性腸疾患などに関与する重要なキナーゼです。JAK1を標的とする低分子阻害剤は、これらの疾患の治療に有効性を示しています。JAK1およびJAK2阻害活性を有する低分子は、関節リウマチ、乾癬、皮膚そう痒症においても治療効果を示しています。JAK3選択的阻害剤やJAK1/TYK2二重阻害剤は、炎症性疾患や自己免疫疾患における治療選択肢の可能性を秘めています。

ヤヌスキナーゼ（JAK）阻害剤市場は、新薬の発見・開発・商品化に対するメーカーの取り組みの活発化、標的疾患の有病率の上昇、新規治療に対する需要の増加などの要因によって、将来的に有利な成長が見込まれます。

市場力学：

促進要因と抑制要因

製品開発活動および市場承認の拡大

ヤヌスキナーゼ（JAK）阻害剤市場は、製品開発活動の活発化とそれに続く市場承認によって大きく牽引されると予想されます。既存メーカーや新興企業は、新規JAK阻害剤の開発に積極的に取り組んでおり、承認されたJAK阻害剤の新たな適応症を探索するための臨床試験も幅広く実施しています。

例えば、2023年に米国食品医薬品局（FDA）は、GSK Plcが開発したJAK阻害剤Ojjaaraを骨髄線維症患者の治療薬として承認しました。Omjjaaraはその後、2024年1月にEUと英国でも同じ適応症で承認されました。

さらに2023年4月、欧州委員会（EC）は、アッヴィが開発したJAK阻害剤リンボックを、1種類以上の腫瘍壊死因子（TNF）製剤で効果不十分または不耐容の中等症から重症の活動期クローン病成人患者の治療薬として承認しました。その後、2023年5月に米国FDAは同じ適応症でRinvoqを承認しました。

このような製品上市の増加は、アンメットニーズの高い様々な治療領域で大きな牽引力となり、市場全体の成長を促進すると期待されます。

ヤヌスキナーゼ（JAK）阻害剤に伴う副作用が市場成長を抑制する可能性

ヤヌスキナーゼ（JAK）阻害剤は、いくつかの免疫関連疾患の治療シナリオに革命をもたらすもの、一定のリスクと副作用を伴う。JAK阻害剤の重大な副作用には、感染症、心血管イベント（脳卒中、塞栓症、血栓症など）、新生物のリスク増加が含まれます。

2022年5月にNature誌Scientific Reportsに発表された研究では、最初に承認された3種類のJAK阻害剤（ルキソリチニブ、トファシチニブ、バリシチニブ）に関連する有害事象が評価されました。WHOのファーマコビジランスデータベースから126,815件の報告を評価した結果、最も多く報告された有害事象は以下の通りでした。

• 感染症、特にヘルペス、インフルエンザなどのウイルス感染症、真菌感染症、マイコバクテリア感染症の発生率の増加。筋骨格系および結合組織障害血栓症や塞栓症などの心血管イベントがん、特に悪性皮膚新生物。

副作用は生命を脅かし、患者の予後を損なう可能性があります。これは採用率の低下につながり、市場の成長を損なう可能性があります。

このレポートの詳細について- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新たな製品開発活動の高まり
    • 疾患修飾治療薬の需要増加
    • パートナーシップとコラボレーションの拡大- 市場アクセスの改善
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 製品別

• アブロシチニブ
• バリシチニブ
• デルゴシチニブ
• フェドラチニブ
• ルキソリチニブ
• トファシチニブ
• ウパダシチニブ
• その他

第7章 機構別

• 可逆的阻害剤
• 不可逆的阻害剤

第8章 適応症別

• 関節リウマチ
• 乾癬性関節炎
• 強直性脊椎炎
• 湿疹
• 円形脱毛症
• 骨髄線維症
• 潰瘍性大腸炎
• 移植片対宿主病（GVDH）
• 真性多血症
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Eli Lilly and Company.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Bristol Myers Squibb company.
• GSK.Plc
• Pfizer Inc.
• Incyte.
• AbbVie Inc.
• Astellas Pharma Inc
• LEO Pharma A/S
• Torii Pharmaceutical Co.,Ltd
• Sobi, Inc.
• Alfasigma Group
• Asana BioSciences, LLC.

第12章 付録

The global Janus Kinase (JAK) Inhibitors market reached US$ 13.23 billion in 2023 and is expected to reach US$ 29.76 Billion by 2032, growing at a CAGR of 8.4% during the forecast period 2024-2032.

Pipeline Drugs

Janus kinase is a group of proteins that are involved in the cytokine signaling pathway. These are known to play a crucial role in several autoimmune, allergic, and inflammatory conditions. There are notably four Janus kinase (JAK) proteins, named JAK1, JAK2, JAK3, and TYK2. These interact with seven signal transducers and activators of transcription (STAT) transcription factors to mediate intracellular signal transduction downstream of cytokine receptors.

Janus Kinase (JAK) inhibitors are drugs indicated in various conditions and are specifically known to inhibit the Janus kinase pathway. JAK1 is a key kinase involved in pruritic dermatitis, allergic rhinitis, asthma, and inflammatory bowel disease. Small-molecule inhibitors targeting JAK1 have shown efficacy in treating these diseases. Small molecules with JAK1 and JAK2 inhibitory activity have also provided therapeutic benefits in rheumatoid arthritis, psoriasis, and pruritis. JAK3 selective inhibitors and JAK1/TYK2 dual inhibitors have potential therapeutic options in inflammatory and autoimmune diseases.

The market for Janus Kinase (JAK) inhibitors is expected to see lucrative growth in the future driven by factors such as increasing efforts by manufacturers to discover, develop, and commercialize novel drugs, rising prevalence of targeted diseases, and increasing demand for novel therapies.

Market Dynamics: Drivers & Restraints

Rising product development activities and market approvals

The market for janus kinase (JAK) inhibitors is expected to be significantly driven by rising product development activities and subsequent market approvals. Established manufacturers and emerging players are actively involved in developing novel JAK inhibitors and also extensively conducting clinical trials to explore new indications for the approved JAK inhibitors.

For instance, in 2023, the U.S. Food and Drug Administration (FDA) approved Ojjaara, a JAK inhibitor developed by GSK Plc, for the treatment of myelofibrosis patients. Omjjaara was then approved in the EU and UK in January 2024 for the same indication.

Moreover, in April 2023, the European Commission (EC) approved Rinvoq a JAK inhibitor developed by AbbVie for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF). Subsequently, in May 2023, the U.S. FDA approved Rinvoq for the same indication.

This increasing product launch is expected to create significant traction in various therapeutic areas with high unmet needs and propel the overall market growth.

The side effects associated with Janus Kinase (JAK) inhibitors may restrain the market growth.

Janus kinase (JAK) inhibitors, although revolutionizing the treatment scenario for several immunity-related conditions, are associated with certain risks and side effects. The serious side effects of JAK inhibitors include increased risk for infections, cardiovascular events (stroke, embolism, thrombosis, etc), and neoplasms.

A study published in The Nature Journal Scientific Reports in May 2022, has evaluated the adverse events associated with the first three approved JAK inhibitors: ruxolitinib, tofacitinib, and baricitinib. The sutdy evaluated 126,815 reports from the WHO pharmacovigilance database, and the most common adverse events reported are

• Increased incidence of infectious disease, especially viral infections such as herpes, influenza, fungal infections, and mycobacterial infectious disorders.
• Musculoskeletal and connective tissue disorders
• Cardiovascular events such as thrombosis and embolism
• Cancers especially malignant skin neoplasms.

The adverse effects are life-threatening and can impair the patient's outcome. This can lead to a decreased adoption rate and may impair market growth.

For more details on this report - Request for Sample

Segment Analysis

The global Janus Kinase (JAK) Inhibitors market is segmented based on Product, mechanism, indication, and region.

Upadacitinib is growing with the highest CAGR in the product segment of the Janus Kinase (JAK) Inhibitors market.

Upadacitinib sold under the brand name Rinvoq is a JAK inhibitor approved for the treatment of multiple indications including eczema, psoriatic arthritis, non-radigraphic axial spondyloarthritis, Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis etc. Among children, the drug is approved for active polyarticular juvenile idiopathic arthritis and active psoriatic arthritis. Rinovoq is manufactured by AbbVie and is available as a once-daily pill for all the above indications.

The drug is approved in major markets such as North America, European Union, and Japan for different indications.

Rinvoq sales are skyrocketing each year, majorly due to expanding applications, and geographic reach. AbbVie has generated US$ 47 million in the launch year 2019 and has generated US$ 3.97 billion in 2023, which is a growth of 203% in 4 years.

Moreover, AbbVie is expanding the clinical applications of Rinvoq by exploring its potential in newer indications. Rinvoq is being explored in phase 3 clinical trials for Alopecia Areata, Hidradenitis Suppurativa, Systemic Lupus Erythematosus (SLE), Takayasu Arteritis, and Vitiligo. This can further boost Rinvoq sales in the forecasted period.

Geographical Analysis

North America is expected to hold a significant share of the Janus Kinase (JAK) Inhibitors market.

North America currently holds a significant market share in the Janus Kinase (JAK) Inhibitors market due to various factors including, higher demand for novel therapies, major revenue generated by market players, and higher prevalence of autoimmune disorders. Any emerging drug is expected to first get launched in the U.S. market due to higher demand, and all the Janus Kinase (JAK) Inhibitors in the current market were first launched in the U.S., providing first access to the patients in the country. Due to higher per-capita income and spending on healthcare, the Janus Kinase (JAK) Inhibitors are sold at higher prices in the North America market as compared to other nations. Due to this, manufacturers generate a majority of their revenue from the region.

For instance, below are the top 5 selling Janus kinase (JAK) inhibitors and their revenue share by region. The top 5 selling drugs generated approximately US$ 11 billion in 2023, of which nearly 62% is from the U.S. This represents the dominance of the region in the global market.

Competitive Landscape

The major global players in the Janus Kinase (JAK) Inhibitors market are Eli Lilly and Company., Bristol Myers Squibb company., GSK Plc., Pfizer Inc., Incyte., AbbVie Inc., Astellas Pharma Inc, LEO Pharma A/S, Torii Pharmaceutical Co.,Ltd, and Sobi, Inc. among others.

Emerging Players

The emerging players in the Janus Kinase (JAK) Inhibitors market include Alfasigma Group, and Asana BioSciences, LLC., HIGHLIGHTLL PHARMA, Akeso Biopharma Co., Ltd. among others.

Key Developments

• In July 2024, the U.S. Food and Drug Administration approved LEQSELVI (deuruxolitinib) for treating adults with severe alopecia areata. LEQSELVI is an oral Janus Kinase (JAK) inhibitor developed by Sun Pharmaceutical Industries Limited and is available at a dose of 8mg tablets.
• In September 2023, the U.S. Food and Drug Administration approved OJJAARA (momelotinib) a Janus Kinase (JAK) inhibitor for treating myelofibrosis patients with anemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor developed by GSK, and can treat anemia, constitutional symptoms, and splenomegaly in myelofibrosis patients.
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Janus Kinase (JAK) Inhibitors market report would provide approximately 68 tables, 65 figures, and 230 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Mechanism
• 3.3. Snippet by Indication
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Novel Product Development Activities
    • 4.1.1.2. Rising Demand for Disease Modifying Therapeutics
    • 4.1.1.3. Rising Partnerships and Collaboration - Improved Market Access
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Treatment
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Product

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Abrocitinib*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Baricitinib
• 6.4. Delgocitinib
• 6.5. Fedratinib
• 6.6. Ruxolitinib
• 6.7. Tofacitinib
• 6.8. Upadacitinib
• 6.9. Others

7. By Mechanism

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Reversible Inhibitors*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Irreversible Inhibitors

8. By Indication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 8.1.2. Market Attractiveness Index, By Indication
• 8.2. Rheumatoid Arthritis*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Psoriatic Arthritis
• 8.4. Ankylosing Spondylitis
• 8.5. Eczema
• 8.6. Alopecia Areata
• 8.7. Myelofibrosis
• 8.8. Ulcerative Colitis
• 8.9. Graft-Versus-Host Disease (GVDH)
• 8.10. Polycythemia Vera
• 8.11. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Eli Lilly and Company. *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Bristol Myers Squibb company.
• 11.3. GSK.Plc
• 11.4. Pfizer Inc.
• 11.5. Incyte.
• 11.6. AbbVie Inc.
• 11.7. Astellas Pharma Inc
• 11.8. LEO Pharma A/S
• 11.9. Torii Pharmaceutical Co.,Ltd
• 11.10. Sobi, Inc.
• 11.11. Alfasigma Group
• 11.12. Asana BioSciences, LLC.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us